For the young cohort, the percentage of HR+/HER2- was highest among patients with bone metastasis (54.1%) and gradually decreased in patients with lung (41.5%), DLN (39.3%), liver (38.3%) and brain (35.3%) metastases. Here, ERBB2 is linked to bone metastasis.